M&A Deal Summary

Nexelis Acquires Pacific Biomarkers

On November 19, 2018, Nexelis acquired life science company Pacific Biomarkers

Acquisition Highlights
  • This is Nexelis’ 1st transaction in the Life Science sector.
  • This is Nexelis’ 1st transaction in the United States.
  • This is Nexelis’ 1st transaction in Washington.

M&A Deal Summary
Date 2018-11-19
Target Pacific Biomarkers
Sector Life Science
Buyer(s) Nexelis
Deal Type Add-on Acquisition

Target

Pacific Biomarkers

Seattle, Washington, United States
Pacific Biomarkers provides specialty biomarker development and central laboratory testing services for the pharmaceutical and biotech markets. The company is a full-service bioanalytical laboratory, capable of supporting pharma sponsors with efficacy and drug safety-related testing from preclinical through Phase IV clinical studies.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nexelis

Laval, Quebec, Canada
Category Company
Sector Life Science
DESCRIPTION

Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules.

DEAL STATS #
Overall 1 of 5
Sector (Life Science) 1 of 5
Type (Add-on Acquisition) 1 of 4
State (Washington) 1 of 1
Country (United States) 1 of 2
Year (2018) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-06 PAIRimmune

Laval, Quebec, Canada

PAIRimmune is a Contract Research Organization specialized in immunology evaluation for vaccine and immunotherapy development. PAIRimmune offers to clients scientific methods combined with biopharma expertise to move forward early biological products. Based on in vivo and in vitro expertise, we build for our industry, academic and small biotech clients an adapted solution for their projects.

Buy -
Mergr

Product

Company

Legal